UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1989) 1989
humans (1891) 1891
life sciences & biomedicine (1891) 1891
cholangiocarcinoma (1491) 1491
oncology (925) 925
male (923) 923
female (830) 830
cholangiocarcinoma - drug therapy (806) 806
cholangiocarcinoma - pathology (771) 771
middle aged (721) 721
aged (630) 630
bile duct neoplasms - pathology (628) 628
cancer (606) 606
bile duct neoplasms - drug therapy (602) 602
gastroenterology & hepatology (493) 493
chemotherapy (473) 473
animals (453) 453
cell line, tumor (437) 437
adult (436) 436
bile ducts, intrahepatic (415) 415
surgery (397) 397
tumors (370) 370
cholangiocarcinoma - metabolism (345) 345
prognosis (343) 343
treatment outcome (334) 334
apoptosis (324) 324
cholangiocarcinoma - genetics (316) 316
bile ducts, intrahepatic - pathology (313) 313
medical prognosis (286) 286
metastasis (279) 279
liver cancer (274) 274
bile duct neoplasms - metabolism (272) 272
cancer therapies (255) 255
liver (255) 255
cholangiocarcinoma - surgery (249) 249
aged, 80 and over (246) 246
deoxycytidine - analogs & derivatives (246) 246
bile duct neoplasms - genetics (236) 236
cholangiocarcinoma - mortality (235) 235
analysis (232) 232
health aspects (227) 227
mice (225) 225
proteins (224) 224
intrahepatic cholangiocarcinoma (223) 223
cholangiocarcinoma - therapy (218) 218
patients (215) 215
antineoplastic combined chemotherapy protocols - therapeutic use (210) 210
bile duct neoplasms - mortality (209) 209
bile duct neoplasms - surgery (208) 208
medicine & public health (206) 206
research (200) 200
hepatocellular carcinoma (195) 195
apoptosis - drug effects (190) 190
kinases (190) 190
gene expression (189) 189
bile duct neoplasms - therapy (184) 184
cholangiocarcinoma - diagnosis (184) 184
gemcitabine (184) 184
cell proliferation - drug effects (181) 181
risk factors (181) 181
retrospective studies (180) 180
immunohistochemistry (165) 165
cell proliferation (156) 156
liver neoplasms - pathology (156) 156
antineoplastic agents - therapeutic use (154) 154
bile duct neoplasms - diagnosis (152) 152
mutation (152) 152
neoplasm staging (151) 151
survival rate (151) 151
cell biology (150) 150
pharmacology & pharmacy (150) 150
studies (150) 150
antineoplastic agents - pharmacology (141) 141
care and treatment (140) 140
liver neoplasms - drug therapy (139) 139
cell cycle (137) 137
cell growth (136) 136
signal transduction (136) 136
deoxycytidine - administration & dosage (133) 133
bile (132) 132
metastases (131) 131
abridged index medicus (129) 129
gastroenterology and hepatology (128) 128
mice, nude (128) 128
survival analysis (126) 126
medicine (125) 125
gene expression regulation, neoplastic (124) 124
research article (121) 121
pathology (119) 119
combined modality therapy (118) 118
survival (118) 118
gastroenterology (114) 114
biliary tract cancer (109) 109
liver transplantation (109) 109
medical research (109) 109
biomarkers (106) 106
review (106) 106
clinical trials (105) 105
biliary tract neoplasms - drug therapy (104) 104
disease-free survival (104) 104
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2508) 2508
Japanese (65) 65
German (19) 19
French (14) 14
Spanish (9) 9
Korean (7) 7
Chinese (5) 5
Danish (3) 3
Portuguese (3) 3
Italian (2) 2
Norwegian (2) 2
Russian (2) 2
Czech (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European journal of cancer (1990), ISSN 0959-8049, 2016, Volume 68, pp. 1 - 10
.... Results Forty-one patients with advanced solid tumours refractory to standard therapies and with adequate organ function were recruited in eight cohorts up to doses of 150... 
Hematology, Oncology and Palliative Medicine | Pharmacodynamics | MEK inhibitor | Phase I | Optimal biological dose | Pharmacokinetics | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Pancreatic Neoplasms - metabolism | Nausea - chemically induced | Allosteric Regulation | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Fatigue - chemically induced | Ribosomal Protein S6 Kinases, 70-kDa - drug effects | Protein Kinase Inhibitors - adverse effects | Colorectal Neoplasms - drug therapy | Chromatography, Liquid | Proto-Oncogene Proteins c-akt - metabolism | MAP Kinase Kinase 1 - antagonists & inhibitors | Bile Duct Neoplasms - metabolism | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | Administration, Oral | Carcinoma, Non-Small-Cell Lung - metabolism | Neoplasms - drug therapy | Maximum Tolerated Dose | Mesothelioma - metabolism | Mitogen-Activated Protein Kinase 3 - metabolism | Anorexia - chemically induced | Glycogen Synthase Kinase 3 beta - drug effects | Mitogen-Activated Protein Kinase 1 - metabolism | Neoplasms - metabolism | Phosphoproteins - drug effects | Mitogen-Activated Protein Kinase 1 - drug effects | Cholangiocarcinoma - metabolism | Chromatography, High Pressure Liquid | Diarrhea - chemically induced | Mitogen-Activated Protein Kinase 3 - drug effects | Pancreatic Neoplasms - drug therapy | Tandem Mass Spectrometry | Uterine Cervical Neoplasms - metabolism | Esophageal Neoplasms - metabolism | Adult | Female | Colorectal Neoplasms - metabolism | Bile Duct Neoplasms - drug therapy | Drug Eruptions - etiology | Abdominal Pain - chemically induced | Uterine Cervical Neoplasms - drug therapy | Glycogen Synthase Kinase 3 beta - metabolism | Mesothelioma - drug therapy | Cholangiocarcinoma - drug therapy | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Aged | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Esophageal Neoplasms - drug therapy | Proto-Oncogene Proteins c-akt - drug effects | Care and treatment | Protein kinases | Mitogens | Cells | Tumors | Index Medicus
Journal Article
Gynecologic oncology, ISSN 0090-8258, 03/2018, Volume 148, Issue 3, pp. 507 - 514
•Phase I study of veliparib+carboplatin/gemcitabine in advanced solid tumors.•MTD/RP2D was veliparib 250mg BID, carboplatin AUC 4, and gemcitabine... 
Phase I | BRCA1/2 mutations | Veliparib | PARP inhibitor | Ovarian cancer | Oncology | Life Sciences & Biomedicine | Obstetrics & Gynecology | Science & Technology | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Nausea - chemically induced | Area Under Curve | Humans | Middle Aged | Ovarian Neoplasms - pathology | Induction Chemotherapy | Male | Ovarian Neoplasms - genetics | Neoplasm Metastasis | Carcinoma, Hepatocellular - drug therapy | Benzimidazoles - administration & dosage | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Maintenance Chemotherapy | Genes, BRCA1 | Neutropenia - chemically induced | Ovarian Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Bile Duct Neoplasms - drug therapy | Deoxycytidine - administration & dosage | Liver Neoplasms - drug therapy | Anemia - chemically induced | Carboplatin - administration & dosage | Treatment Outcome | Thrombocytopenia - chemically induced | Breast Neoplasms - drug therapy | Mesothelioma - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Kidney Pelvis | Maximum Tolerated Dose | Breast Neoplasms - genetics | Carcinoma, Squamous Cell - drug therapy | Gallbladder Neoplasms - drug therapy | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Bayes Theorem | Carcinoma, Transitional Cell - drug therapy | Carcinoma, Basal Cell - drug therapy | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Kidney Neoplasms - drug therapy | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article
Nature medicine, ISSN 1546-170X, 11/2017, Volume 23, Issue 12, pp. 1424 - 1435
Human liver cancer research currently lacks in vitro models that can faithfully recapitulate the pathophysiology of the original tumor. We recently described a... 
Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Cell Biology | Research & Experimental Medicine | Cell Proliferation | Primary Cell Culture - methods | Humans | Gene Expression Regulation, Neoplastic | Transcriptome | Male | Antineoplastic Agents - therapeutic use | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - isolation & purification | Carcinoma, Hepatocellular - genetics | Liver Neoplasms - pathology | Bile Duct Neoplasms - genetics | Tumor Cells, Cultured | Bile Duct Neoplasms - drug therapy | Precision Medicine | Drug Screening Assays, Antitumor - methods | Organoids - pathology | Liver Neoplasms - genetics | Liver Neoplasms - drug therapy | Mice, SCID | Xenograft Model Antitumor Assays | Cholangiocarcinoma - pathology | Animals | Cholangiocarcinoma - drug therapy | Carcinoma, Hepatocellular - pathology | Cholangiocarcinoma - genetics | Mice, Inbred NOD | Mice | Bile Duct Neoplasms - pathology | Cell culture | Liver cancer | Development and progression | Usage | Models | Research | Propagation | Liver | Extracellular signal-regulated kinase | Hepatocellular carcinoma | Pharmacology | Gene expression | Tissues | Drug screening | Chemical compounds | Metastases | Screening | Utilities | Biomedical materials | Hepatocytes | Organoids | Xenografts | Biomarkers | In vivo methods and tests | Cholangiocarcinoma | Tumors | Cancer | Index Medicus
Journal Article
Cellular and molecular life sciences : CMLS, ISSN 1420-682X, 2017, Volume 74, Issue 6, pp. 1133 - 1151
Journal Article
Biomedical microdevices, ISSN 1387-2176, 3/2018, Volume 20, Issue 1, pp. 1 - 8
This study aimed to investigate the drug delivery efficacy and bio-effectiveness of a novel photodynamic therapy (PDT... 
Biomedical Engineering | Engineering | Photodynamic therapy (PDT) | Engineering Fluid Dynamics | Biological and Medical Physics, Biophysics | Stent | Nanotechnology | Cholangiocarcinoma | Science & Technology - Other Topics | Nanoscience & Nanotechnology | Technology | Engineering, Biomedical | Science & Technology | Drug-Eluting Stents | Dihematoporphyrin Ether - administration & dosage | Drug Delivery Systems - instrumentation | Reactive Oxygen Species - metabolism | Bile Duct Neoplasms - metabolism | Dihematoporphyrin Ether - pharmacokinetics | Apoptosis - drug effects | Photochemotherapy - methods | Humans | Antineoplastic Agents - administration & dosage | Cholangiocarcinoma - metabolism | Methacrylates - chemistry | Polymethacrylic Acids - chemistry | Cholangiocarcinoma - pathology | Cholangiocarcinoma - drug therapy | Photochemotherapy - instrumentation | Cell Line, Tumor | Drug Liberation | Antineoplastic Agents - pharmacokinetics | Bile Duct Neoplasms - pathology | Drug Delivery Systems - methods | Polyvinyls - chemistry | Bile Duct Neoplasms - drug therapy | Drugs | Medical colleges | Ethylene glycol | Drug delivery systems | Benzoyl peroxide | Photochemotherapy | Vinyl acetate | Stent (Surgery) | Cancer | Vehicles | Medical imaging equipment | Polyurethane resins | Surgical implants | Membranes | Photodynamic therapy | Ethylene | Stenosis | Polyvinylpyrrolidone | Drug delivery | Diffusion layers | Polyhydroxyethyl methacrylate | Peroxide | Polyurethane | Implants | Diffusion | Acetic acid | Stents | Species diffusion | Apoptosis | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 08/2015, Volume 373, Issue 8, pp. 726 - 736
Journal Article
British journal of cancer, ISSN 0007-0920, 01/2010, Volume 102, Issue 1, pp. 68 - 72
Journal Article
PLoS genetics, ISSN 1553-7404, 02/2014, Volume 10, Issue 2, pp. e1004135 - e1004135
.... New advances in drug treatment have enabled treatment of these cancers with "targeted therapy" that exploits an error in the normal functioning of a tumor cell, compared to other cells in the body... 
Life Sciences & Biomedicine | Genetics & Heredity | Science & Technology | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - genetics | Prognosis | Receptor, Fibroblast Growth Factor, Type 2 - metabolism | Humans | Transcriptome | Imidazoles - administration & dosage | Molecular Targeted Therapy | Receptor, Epidermal Growth Factor - metabolism | Pyridazines - administration & dosage | Quinazolines - administration & dosage | Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors | Bile Duct Neoplasms - genetics | Bile Duct Neoplasms - drug therapy | Bile Ducts, Intrahepatic - pathology | Pyrimidines - administration & dosage | Signal Transduction - genetics | Cholangiocarcinoma - pathology | Protein Kinase Inhibitors | Cholangiocarcinoma - drug therapy | Cell Line, Tumor | Cholangiocarcinoma - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Bile Duct Neoplasms - pathology | Mutation | Genome, Human | Receptor, Fibroblast Growth Factor, Type 2 - genetics | Sulfonamides - administration & dosage | Antimitotic agents | Analysis | Genomics | Research | Antineoplastic agents | Health aspects | Tumors | Index Medicus | Studies | Hepatitis | Substance abuse treatment | Genetic engineering | Genomes | Kinases | Gene expression | Patients | Cancer
Journal Article